Real World Observational Study of Pembrolizumab for Chinese Advanced NSCLC

Zhejiang University

Status: Enrolling

Conditions: Non-small Cell Lung Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT04153097

ZYHX-001

Details and patient eligibility

About

This observational study is designed to assess the efficacy and safety of pembrolizumab for the treatment of Chinese advanced NSCLC.

Full description

Pembrolizumab is a humanized antibody used in cancer immunotherapy.The NMPA(China) approved pembrolizumab for first-line treatment of certain patients with advanced NSCLC.

This is a multi-center non-interventional study, advanced NSCLC patients who treated with pembrolizumab and provide written informed consent will be included. The main objective of this study is to evaluate pembrolizumab efficacy and safety in the clinical practice and explore the prognosis-relevant factors of advanced NSCLC.

Enrollment: 500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Histologically or cytologically confirmed diagnosis of advanced or metastatic NSCLC
2. Patients who receive pembrolizumab for advanced NSCLC.
3. Patients who provided written informed consent.

Exclusion criteria

1.Patients who would join any interventional clinical studies from first diagnosis to the end of the pembrolizumab treatment

Trial design

500 participants in 1 patient group

pembrolizumab-treated advanced NSCLC

Description:

Patients with advanced non-small cell lung cancer treated with pembrolizumab